Management of Bacillus Calmette-Guerin osteomyelitis/osteitis in immunocompetent children-A systematic review
Resource
Vaccine, 33(36), 4391-4397
Journal
Vaccine
Journal Volume
33
Journal Issue
36
Pages
4391-4397
Date Issued
2015
Date
2015
Author(s)
Lin, Wen-Li
Chiu, Nan-Chang
Lee, Pin-Hui
Huang, Angela Song-En
Huang, Fu-Yuan
Chi, Hsin
Huang, Daniel Tsung-Ning
Chan, Pei-Chun
Abstract
Background: Bacillus Calmette-Guerin (BCG) osteomyelitis/osteitis in immunocompetent children is a rare but serious complication of BCG immunization. Rationale for its treatment is unclear. ;Methods: Due to the rarity of this complication, no randomized control trials has ever been conducted to evaluate methods of intervention. As such, we searched the literature for any reported BCG vaccination-related osteomyelitis/osteitis among immunecompetent children published before April 15, 2014. We summarized the data from different affected regions of the body by recording the number of reported cases, while noting outcomes and their medical and/or surgical interventions. ;Results: From 34 eligible studies gleaned from a screening of 804 articles, a total of 331 cases were enrolled. Involvement of the lower limbs was present in 55.6%, followed by the axial skeleton (26.0%), the upper limbs (15.4%), and multiple bones (3.0%). Of the 64 patients having records of detailed chemotherapy regimens, 45 patients (70%) received two or fewer drugs. Among the 80 patients with detailed surgical records, 50 (62.5%) received surgical procedures for diagnostic purposes. While there were uneventful outcomes for those receiving diagnostic procedures, 7 of the 30(23.3%) patients receiving surgical interventions had major complications (p= 0.002, Fisher's exact test). The overall prognosis was good with a 97.6% cure rate. Nevertheless, eight patients (2.4%) suffered major complications. ;Conclusions: The rationale for treatment of BCG osteomyelitis/osteitis in immunocompetent children is highly subjective. However, patients receiving diagnostic procedures instead of surgical interventions may avoid major complications. Because only a few of the publications had detailed treatment information, further studies are needed to identify proper treatments, while infant BCG vaccination is still in use. (C) 2015 Elsevier Ltd. All rights reserved.
Subjects
BCG vaccine
Osteomyelitis
Osteitis
Disease management
Review
SDGs
Other Subjects
BCG vaccine; ethambutol; isoniazid plus rifampicin; pyrazinamide; streptomycin; BCG vaccine; tuberculostatic agent; antimicrobial therapy; arm; BCG vaccination; bone biopsy; child; fine needle aspiration biopsy; histopathology; human; immunocompetence; leg; limb deformity; mortality; mycobacteriosis; onset age; orthopedic surgery; osteitis; osteomyelitis; outcome assessment; paralysis; pediatric surgery; polymerase chain reaction; postoperative complication; priority journal; prognosis; range of motion; Review; scoliosis; skeleton; systematic review; vaccination reaction; weakness; adolescent; chemically induced; debridement; infant; newborn; osteomyelitis; preschool child; Adolescent; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Debridement; Humans; Infant; Infant, Newborn; Osteomyelitis